Form 4 · Filed Jun 11, 2026, 09:30 PM UTC
QNCX/Quince Therapeutics, Inc.
Roberts Brigette — Chief Corp. Affairs Officer
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
9 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026 | A | other | 34,675 | — | — | 34,675 |
| May 18, 2026 | A | other | 228,855 | — | — | 228,855 |
| May 18, 2026 | A | other | 124,830 | — | — | 124,830 |
| May 18, 2026 | A | other | 69,350 | — | — | 69,350 |
| May 18, 2026 | A | other | 362,092 | — | — | 362,092 |
| May 18, 2026 | A | other | 133,615 | — | — | 133,615 |
| May 18, 2026 | A | other | 2,070,107 | — | — | 2,070,107 |
| May 18, 2026 | A | other | 6,837,319 | — | — | 6,837,319 |
| May 18, 2026 | A | other | 6,837,319 | — | — | 6,837,319 |
Source: SEC EDGAR raw filing ↗ · Accession 0001346566-26-000004